|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
RED CELLS
From the Institut National de la Santé et de la
Recherche Médicale (INSERM) U76, Institut National de la
Transfusion Sanguine (INTS); and (D.D.) INSERM U409, Faculté de
Médecine Xavier Bichat, Paris, France.
In most cases, the lack of Rh in Rhnull red cells is
associated with RHAG gene mutations. We explored the role
of RhAG in the surface expression of Rh. Nonerythroid HEK293 cells,
which lack Rh and RhAG, or erythroid K562 cells, which endogenously express RhAG but not Rh, were transfected with RhD and/or RhAG cDNAs using cytomegalovirus (CMV) promoter-based expression
vectors. In HEK293 cells, a low but significant expression of RhD was
obtained only when RhAG was expressed at a high level. In K562 cells,
as expected from the opposite effects of the phorbol ester
12-O-tetradecanoyl phorbol 13-acetate (TPA) on erythroid
and CMV promoters, the levels of endogenous RhAG and recombinant RhD
transcripts were substantially decreased and enhanced upon TPA
treatment of RhD-transfected cells (K562/RhD), respectively. However,
flow cytometry and fluorescence microscopy analysis revealed a
decreased cell-surface expression of both RhAG and RhD proteins.
Conversely, TPA treatment of RhAG-transfected cells increased both the
transcript and surface expression levels of RhAG. When K562/RhD cells
were cotransfected by the RhAG cDNA, the TPA-mediated induction of
recombinant RhAG and RhD transcription was associated with an increased
membrane expression of both RhAG and RhD proteins. These results
demonstrate the role of RhAG as a strictly required posttranscriptional
factor regulating Rh membrane expression. In addition, because the
postulated 2:2 stoichiometry between Rh and RhAG observed in the native
red cell membrane could not be obtained in cotransfected K562 cells,
our study also suggests that as yet unidentified protein(s) might be
involved for optimal membrane expression of Rh.
(Blood. 2002;100:1038-1047) The Rh antigens are defined by the association of
membrane polypeptides, which are missing from or severely reduced in
red blood cells (RBCs) of rare Rhnull individuals. These
individuals suffer from a clinical syndrome characterized by
abnormalities of the red cell shape, cation transport, and membrane
phospholipid organization (reviewed by Cartron1 and Huang
et al2). The core of this complex is thought to be a
tetramer composed of 2 Rh and 2 RhAG subunits,3 with which
accessory chains (CD47, LW, and glycophorin B [GPB]) are
associated by noncovalent linkages.4-7 Rh and RhAG
proteins are erythroid specific and are encoded by homologous
genes.8,9 Furthermore, nonerythroid homologues of RhAG are
present in other tissues, thus defining an "RH gene superfamily."10 In addition, RhAG might play a role in
RBCs by participating in the linkage of the membrane cytoskeleton to the phospholipid bilayer and by exhibiting ammonium transport activity.11
The RH locus is composed of the RHD and
RHCE genes, which are organized in tandem on chromosome
1p34-p36.12 The RHD gene, however, is absent
from most white individuals of the RhD-negative phenotype.13 RhD and RhCcEe polypeptides are
nonglycosylated, fatty-acylated proteins that span the lipid bilayer 12 times.14 The RHAG locus (chromosome 6p11-p21)
encodes a glycosylated protein with the same membrane topology as Rh
proteins.15-17 Although the RH locus is highly
polymorphic, the few mutations of the RHAG gene described so
far all resulted in defective membrane expression of RhAG in
Rhnull individuals.1,2,16,18
A current model suggests that the Rh complex is not assembled or
transported to the cell surface when one subunit is missing. However,
molecular analysis of Rhnull individuals has revealed that
abnormalities occurred only at the RH and RHAG
loci, without alteration of the genes encoding CD47, LW, and
GPB.1,2,18 This correlates well with the description of
rare individuals whose RBCs selectively lack GPB or LW glycoproteins
and are not deficient in Rh, RhAG, and CD47 proteins. Human RBCs
selectively deficient in CD47 have not been described, but RBCs from
CD47 Although Rh and RhAG both appear critical for surface expression of Rh
antigens, they differ notably by the factors that determine their
cell-surface expression. Indeed, whereas Rh proteins have never been
found in the absence of RhAG, Rh proteins may be partially dispensable
for the routing of RhAG to the membrane, as suggested by the following
evidence: (1) A significant level of RhAG was detected on
Rhnull RBCs, which lack detectable Rh
proteins21 from patients carrying RH gene
mutations; and (2) erythroleukemic K562 cells that either
lacked22 or expressed a very low amount of Rh
antigen23 expressed 6 to 9 × 104 copies of
RhAG24; and (3) RhAG was expressed before Rh proteins during the differentiation of erythroid progenitors in
vitro.25,26 Therefore, there is a need to develop
expression systems that may clarify how Rh and RhAG proteins may
interact in vivo to build a cell-surface complex expressing Rh antigens.
Expression of recombinant human RhCE and RhD proteins in
erythroleukemic K562 cells using a retroviral expression system has proved useful to demonstrate the genetic basis of the major Rh antigens.27-30 We report here a cellular model in which
recombinant expression of Rh and RhAG was achieved after standard
plasmid cell transfection. Most important, by coupling this
heterologous expression system with the property of the phorbol ester
TPA (12-O-tetradecanoyl phorbol 13-acetate) to repress or
induce the transcriptional activity of genes under the control of
erythroid and cytomegalovirus (CMV) promoters, respectively, we
demonstrate the role of RhAG as a critical posttranscriptional factor
regulating membrane expression of Rh polypeptides in K562 cells. We
also show for the first time that a significant, albeit low, expression
level of Rh can be achieved in a nonerythroid cell line cotransfected
by RhD and RhAG cDNAs.
Antibodies
Expression vectors
Cell culture, transfection, and cell sorting K562 (human erythroleukemia) and HEK293 (human embryonal kidney) cells (American Type Culture Collection, Rockville, MD) were grown, respectively, in RPMI 1640 and Dulbecco modified Eagle medium containing 10% fetal calf serum (FCS). A total of 1 × 107 K562 cells were transfected with 35 µg pcDNA3-RhD vector using Lipofectin reagent (Life Technologies, Gaithersburg, MD) and were maintained in G418-containing medium (800 µg/mL Geneticin; Life Technologies). After 2 weeks, a neomycin-resistant pool of K562 cells was incubated with an anti-D (F5) hMAb and mixed with BioMag magnetic beads coated with anti-human IgG Fc-specific antibody (Bio Advance, Emerainville, France). Cells that were retained by the magnet after several washes were recultured in RPMI/FCS 10% supplemented with G418 (800 µg/mL) and then transferred to a 96-well microplate after limiting dilution. After 2 weeks, neomycin-resistant stably transfected clones were transferred to 24-well plates and expanded before flow cytometric analysis. These transfections generated the K562/RhD clones. A total of 5 × 106 HEK293 cells were transfected with 10 µg pCEP4-RhAG vector in 400 µL phosphate-buffered saline (PBS), HEPES 10 mM, by electroporation (Biorad; 960 µF and 0.230 V) and were maintained in culture medium supplemented with 300 µg/mL hygromycin (Life Technologies).HEK293/RhAG cells transfected by the pREP9-RhD and K562 and K562/RhD cells transfected by the pcDNA-hyg-RhAG vector were maintained in hygromycin-containing (300 µg/mL) medium with or without G418 (800 µg/mL). After 2 weeks, hygromycin K562-resistant cells were grown to a density of approximately 6 × 105/mL, and TPA (Sigma, St Louis, MO) was added in culture medium at a final concentration of 0.05 µg/mL. After 24 hours, TPA-treated K562 cells were sorted by an anti-RhAG (2D10) MAb using a FACS Vantage cytometer (Becton Dickinson, San Jose, CA). TPA-treated K562/RhD cells were sorted by magnetic beads (CELLection pan Mouse IgG Kit; Dynal, Oslo, Norway) using an anti-Rh polypeptide mMAb (clone BRIC69). Sorted cells were recultured in RPMI/FCS 10% supplemented with hygromycin (300 µg/mL) with or without G418 (800 µg/mL). The cells were then subjected to limiting dilution cloning in 96-well microplates before expanding for flow cytometry analysis. These sequential transfections generated K562/RhAG and K562/RhD/RhAG clones. K562 or K562/RhD cells transiently transfected by the pcDNA-RhAG and pcDNA3-K2 (control) vectors were treated with TPA after 24 hours of culture. Flow cytometric analyses were performed 48 hours after the treatment on K562 cells and 48 hours after the transfection on HEK293 cells. Flow cytometric analysis K562 or HEK293 cells (5 × 105) were resuspended in 50 µL PBS/0.2% (wt/vol) bovine serum albumin (BSA) and incubated for 30 minutes at 4°C or 27°C with mMAbs or hMAbs, respectively. After several washes with PBS, cells were incubated for 30 minutes at 4°C or 22°C with fluorescein isothiocyanate (FITC)-conjugated F(ab')2 fragment of goat anti-mouse immunoglobulins (Immunotech, Marseille, France) or with R-phycoerythrin (RPE)-conjugated F(ab')2 fragment of goat anti-human immunoglobulins (Immunotech), respectively. In double immunostaining (2-color labeling) experiments, sequential incubations with human anti-D, anti-human RPE-F(ab')2, mouse anti-RhAG, and anti-mouse FITC F(ab')2 were performed in the conditions described above. After a common excitation at 488 nm, the fluorescence was measured at 515 to 545 nm for FITC and 564 to 606 nm for PE. With an additional excitation at 630 nm, a third fluorescence measurement at 653 to 669 nm using the TO-PRO-3 iodide (Interchim, Montluçon, France) allowed exclusion of dead cells from analysis. Fluorescence was measured on a FACSCalibur flow cytometer (Becton Dickinson). When using anti-mouse antibodies, we quantified the cell-surface antigen expression using calibration mouse IgG-coated beads (Qifikit; DAKO, Glostrup, Denmark) as standards, according to the manufacturer's instructions. The results were expressed as specific antibody-binding capacity (SABC) units, which proved to be directly proportional to the number of molecules bound per cell.Immunofluorescence microscopy K562 cells were washed in PHEM buffer, pH 6.9 (K-PIPES 60 mM, HEPES 25 mM, EGTA 1 mM, Mg-acetate 1 mM), spread on glass slides, and fixed with 4% paraformaldehyde for 20 minutes. After washes in PBS, the cells were treated by 50 mM NH4Cl to block aldehyde groups. After washes in PBS, cells were permeabilized with 0.5% Triton X-100 for 10 minutes. Cells were then blocked with a solution of 0.1% BSA in PBS for 10 minutes and incubated simultaneously with appropriate dilutions of mMAbs and hMAbs for 1 hour. After 3 washes in PBS containing BSA, the cells were stained with Alexa-Fluor 488-conjugated anti-mouse and Alexa-Fluor 568-conjugated anti-human IgG (Molecular-Probes, Interchim, Asnières, France). After washes in PBS, the stained cells were mounted in Slow Fade Light antifade (Molecular-Probes, Interchim). Fluorescence was observed with a Leica TCS (Leica, Rueil Malmaison, France) equipped with a krypto-argon laser, a 63/1.4 oil objective lens, and a simultaneous dual-channel detector.Immunoprecipitation of RhD and RhAG polypeptides from K562 cells K562 and K562/RhD/RhAG cells were labeled with [35S]-methionine (Amersham) (400 µCi [14.8 MBq]/107 cells) for 3 hours in 0.5 mL methionine-free RPMI. After 3 washes with ice-cold PBS, cells were incubated with 200 µL lysis buffer (PBS containing 1% Triton X-100 with complete EDTA-free protease inhibitors; Roche, Meylan, France) for 30 minutes at 4°C and centrifuged. A total of 800 µL buffer A (PBS containing sodium dodecyl sulfate [SDS] 0.1%, Triton X-100 0.5%, EDTA 5 mM, BSA 0.5%) was added to the supernatant. This was separated in 2 aliquots of 0.5 mL, one of which was incubated with 10 µL MPC8 rabbit anti-Rh antibody and the other with 100 µL LA18.18 anti-RhAG mMAb overnight at 4°C. The immune complexes extracted by Protein A-Sepharose (Amersham Pharmacia Biotech) were run on SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and the dried gels were subjected to autoradiography.Northern blot analysis Total RNAs were extracted from K562 cells using the High Pure RNA Isolation Kit (Roche). RNA samples (10 µg) were resolved by electrophoresis on a 1.1% (vol/vol) formaldehyde, 1% (wt/vol) agarose gel and transferred to nylon filters (Zeta-probe GT; BioRad, Hercules, CA). Hybridization with [32P]-cDNA probes was performed in 7% SDS, 0.5 M NaHPO4 at 65°C for 16 hours. Final washes were performed in 0.1 × SSC, 0.1% SDS (w/v) at 65°C. The probes were as follows: RhAG and RhD cDNAs described above; Lu (1978 bp) and GPA (485 bp) as described37,38; CD44 (1087 bp), CD55 (1394 bp), and CD47 (IAP) (972 bp) obtained by reverse transcriptase (RT)-PCR of lymphocyte RNA using the Superscript One-Step RT-PCR System (Life Technologies); and primers based on published sequences.39-41
HEK293 cells stably expressing the recombinant RhAG and/or RhD polypeptides Cell-surface expression of RhAG polypeptide was investigated by flow cytometry analysis of HEK293 cells transfected by the pCEP4-RhAG plasmid. After 3 weeks of selection in hygromycin-containing medium, a high level (mean fluorescence intensity [MFI] 362) and stable expression of the recombinant protein was detected by the LA18.18 anti-RhAG MAb on pCEP4-RhAG-transfected cells (HEK293/RhAG) but not on untransfected cells (Figure 1A). Using the F5 anti-D MAb, no expression of RhD was detected on both cells (not shown).
HEK293 and HEK293/RhAG cells were also transfected by the pREP9-RhD plasmid. Flow cytometric analysis using the F5 anti-D MAb revealed that a weak but significant transient expression of the RhD polypeptide could be detected on the HEK293/RhAG cells but not on the HEK293 cells 48 hours after transfection (Figure 1B). Stable K562 clone expressing the recombinant RhD polypeptide A G418-resistant K562/RhD cell pool was generated after standard plasmid transfection with the pcDNA3-RhD vector. Flow cytometry performed as soon as a pool of G418-resistant cells could be obtained indicated that the F5 anti-D MAb bound much more strongly to K562/RhD cells than to the control K562/Lu clone expressing the recombinant Lu glycoprotein,42 with a 2-fold increase in MFI (not shown). However, after 2 additional weeks of culture, K562/RhD cells exhibited only a weak increase in RhD antigen expression as compared with K562/Lu cells (Figure 2). Therefore, the cell fraction overexpressing RhD was enriched after the neomycin selection step by mixing magnetic beads coated with anti-human IgG Fc MAb with the K562/RhD cells preincubated with the anti-D MAb. Figure 2 shows that the F5 anti-D MAb bound much more strongly to the sorted than to the unsorted K562/RhD cells or K562/Lu cells. Flow cytometric analysis of a K562/RhD clone obtained showed that MAbs to all the RhD epitopes (9-epitope model) as well as BRIC69 (anti-Rh polypeptide), F5 and LOR-15C9 (anti-RhD), and H2G11 (anti-RhG) bound more strongly to K562/RhD than to K562/Lu cells (Table 1), with a 1.9- to 6.2-fold increase in MFI. Anti-CD47 and anti-LW MAbs showed a 2-fold increase in binding between K562/RhD and K562/Lu cells, whereas MAbs directed against epitopes specific for the RHCE encoded polypeptide (c, E, e) or the anti-RhAG MAb showed no difference between the recombinant clones.
Stable K562 clone expressing the recombinant RhAG glycoprotein Because of the substantial expression of endogenous RhAG (40 000-50 000 molecules/cell), recombinant RhAG could not be distinguished by comparative flow cytometric analysis between mock and transiently RhAG-transfected K562 cells. However, when these cells were treated by TPA, overexpression of RhAG antigen was detected on a small number of cells transfected by pcDNA3-hyg/RhAG. These cells most likely corresponded to the transfected cell subpopulation because, as discussed below, TPA treatment enhanced CMV promoter-based expression of transgenes and abolished expression of endogenous erythroid-specific markers. To derive a K562 clone stably expressing recombinant RhAG, we sorted TPA-treated cells that overexpressed RhAG and recultured them in hygromycin-containing medium without TPA. After limiting dilution cloning, a stable K562/RhAG clone was obtained. As estimated from the binding capacity of the 2D10 MAb, the K562/RhAG clone expressed 3- to 4-fold more RhAG glycoprotein (SABC 133 000 molecules/cell) than control clones stably transfected by Lu or RhD (52 000 and 40 000 molecules/cell, respectively) (Table 2).
Effect of TPA on the expression levels of endogenous and recombinant transcripts in K562 cells TPA treatment of K562 cells has been shown to down-regulate the transcription of erythroid-specific markers such as GPA and PBGD43,44 and to up-regulate transcription of the megakaryocytic differentiation marker CD44.45 The effect of TPA on the endogenous expression of genes encoding the major proteins of the Rh complex (RhAG, Rh, and CD47) was estimated by Northern blot analysis of K562/Lu cells. Figure 3 shows that the endogenous expression of RhAG and Rh transcripts was down-regulated, as expected for erythroid-specific genes, whereas expression of the ubiquitous CD47 gene was not affected. As controls, hybridizations with GPA, CD55, and CD44 probes showed a negative effect, no effect, and a positive effect of TPA, respectively.
TPA treatment was shown to activate the transcriptional activity of the
HCMV MIE enhancer/promoter region.46 In the
pcDNA3 vector, this CMV promoter region regulates expression of
recombinant genes. Therefore, in an attempt to increase expression of
the recombinant RhD and RhAG cDNAs, the K562/RhD and K562/RhAG clones were maintained for 24 or 48 hours in culture medium containing TPA. As
a control, K562/Lu cells were similarly treated. Northern blot analysis
showed that the levels of recombinant RhAG, RhD, and Lu transcripts
were substantially increased by TPA treatment of K562/RhAG, K562/RhD,
and K562/Lu cells, respectively (Figure 4).
Effect of TPA on the expression levels of endogenous and recombinant antigens in K562 cells Flow cytometric analysis of cell-surface antigen expression using specific MAbs fully correlated with Northern blot analysis as regards the effect of TPA on endogenous markers of recombinant K562 clones. TPA treatment resulted in up-regulation and down-regulation of the cell-surface expression of CD44 and GPA, respectively, whereas no effect was detected on CD55 and CD47 expression (not shown).The down-regulation of endogenous RhAG expression was confirmed in
K562/Lu and K562/RhD cells. Endogenous expression of Rh in K562/Lu and
K562/RhAG cells was poorly detectable, but a TPA-mediated down-regulation could be observed (Table 2). Flow cytometric analysis
showed that the TPA-mediated enhancement of recombinant transcripts
resulted in a 4-fold and a 3-fold increase in the surface expression of
the recombinant Lu and RhAG antigens in K562/Lu and K562/RhAG cells,
respectively (Figure 5; Table 2). In
contrast, the surface expression of the recombinant RhD antigen in
K562/RhD cells, as detected by LOR-15C9 and F5 anti-D hMAbs (Figure 5)
or by BRIC69 anti-Rh mMAb (Table 2), exhibited a 5-fold decrease after
24 hours of TPA treatment and was not detectable after 48 hours.
Flow cytometric analysis of K562 and K562/RhD clones transiently transfected with RhAG cDNA To evaluate the postulated role of RhAG in membrane expression of RhD, we transiently transfected K562 and K562/RhD clones with the pcDNA3-RhAG vector. TPA treatment was particularly convenient for extinguishing endogenous expression of RhAG and thus focusing only on the effect of the overexpression of the recombinant RhAG protein. Moreover, transient transfections allowed us to analyze at once several transfected and untransfected K562/RhD cells exhibiting heterogeneous levels of RhAG membrane expression. As controls, these cells were transfected with the empty pcDNA3 vector (mock control) and with a pcDNA3-K2 plasmid. K2 antigen was chosen as irrelevant control because, like RhAG, it is expressed endogenously in K562 cells,47 and therefore, we expected TPA-mediated regulation of endogenous and recombinant K2 antigen expression similar to that described above for RhAG. Simultaneous analysis of RhD and RhAG or RhD and Kell expression was performed by flow cytometry after double immunostaining.Analysis of mock-transfected K562 cells showed that the endogenous
expression of RhAG and K2 antigens was down-regulated by TPA treatment
(Figure 6A,C). Analysis of the TPA effect
on cells transiently transfected by the RhAG or Kell cDNAs revealed 2 cell subpopulations (Figure 6B,D). A major subpopulation, most likely corresponding to nontransfected cells, exhibited a decreased expression of RhAG and Kell upon TPA treatment. However, a TPA-mediated
overexpression of RhAG and Kell antigens was clearly observed in a
small subpopulation of K562 cells transiently transfected by RhAG and
K2 cDNAs, respectively, as compared with mock transfectants. Regarding
RhD expression in TPA-untreated cells, we could not detect a positive
effect of the transient expression of RhAG or, as expected, of Kell
proteins (Figure 6B,D). Furthermore, in contrast to recombinant RhAG
and Kell antigens, the weak endogenous expression of RhD was repressed, as expected, under TPA treatment of mock-, RhAG-, and Kell-transfected cells (Figure 6).
K562/RhD cells transiently transfected by empty, RhAG, and K2
expression vectors (Figure 7) exhibited
TPA responses similar to those discussed above for K562 cells when
endogenous and recombinant RhAG and Kell antigens were analyzed.
However, different results were obtained when RhD expression was
analyzed. First, the LOR-15C9 anti-D MAb bound more strongly
to K562/RhD than to K562 cells (Figures 6A and 7A), as discussed above.
Second, a cell subpopulation exhibiting a substantial increase of RhD
and RhAG surface expression could be detected after TPA treatment of
K562/RhD cells transfected by the RhAG cDNA (Figure 7B), but not by
empty vector (Figure 7A,C). Moreover, the typical tapering shape of the
diagram observed with TPA-treated RhAG-transfected K562/RhD cells
indicates a good correlation between RhAG and RhD antigen expression
levels. As a control, overexpression of the Kell antigen in TPA-treated
K2-transfected cells did not lead to overexpression of RhD (Figure
7D).
Stable K562/RhD/RhAG clone expressing both RhD and RhAG recombinant polypeptides The transient transfection experiments discussed above strongly suggested that overexpression of RhD upon TPA treatment of K562/RhD cells was achieved only in the RhAG-transfected cell subpopulation. To generate K562 cells stably expressing both RhD and RhAG recombinant polypeptides, K562/RhD cells were transfected by the RhAG cDNA cloned in a pcDNA-hyg vector, treated by TPA, and stained with the BRIC69 anti-Rh polypeptide MAb. Cells with the highest expression of RhD were sorted and cultured in medium containing both neomycin and hygromycin. After limiting dilution cloning, a K562/RhD/RhAG stable clone was obtained. Flow cytometric analysis indicated that K562/RhD/RhAG cells, as did the K562/RhAG clone, expressed more RhAG antigen (79 000 copies/cell) than the K562/Lu (52 800 copies/cell) or K562/RhD (40 000 copies/cell) clones (Table 2). As expected from the analysis of the K562/RhAG clone, the K562/RhD/RhAG clone also exhibited a TPA-mediated enhancement (>2-fold) in cell-surface expression of RhAG. The K562/RhD/RhAG cells also bound more strongly the BRIC69 anti-Rh MAb than all other clones, and, more important, did not exhibit a TPA-mediated down-regulation of cell-surface expression of RhD, in contrast to all other clones, including K562/RhD. However, it should be noted that in contrast to RhAG, expression of RhD could not be enhanced by TPA treatment of these cells.Expression of the RhD recombinant polypeptide in the K562/RhD/RhAG
cells was demonstrated by immunoprecipitating the
[35S]-methionine-labeled proteins of the cell lysates
with the MPC8 anti-Rh polypeptide antibody and by analyzing the
immunoprecipitates on SDS-PAGE. As shown in Figure
8A, a 32-kd band corresponding to the Rh
polypeptide was clearly identified (with the same intensity) from
TPA-treated or -untreated K562/RhD/RhAG cell samples, but poorly or not
at all from parental K562 cell samples. Using the same
immunoprecipitation procedure on K562 cells and the LA18.18 monoclonal
anti-RhAG antibody, we found a 32-kd band (Figure 8B) corresponding to
endogenous expression of the partially glycosylated RhAG
protein.48 In agreement with the flow cytometric analysis showing a TPA-mediated down-regulation of endogenous RhAG, the 32-kd
signal was fainter in TPA-treated than in TPA-untreated K562 cell
samples. In contrast, the 32-kd signal detected in the K562/RhD/RhAG
cell sample was clearly enhanced when the cells were treated with TPA
(Figure 8B). These results suggest that this strong signal corresponded
to the expression of recombinant RhAG in TPA-treated K562/RhD/RhAG
cells and indicate that TPA did not affect the glycosylation state of
the RhAG protein in K562 cells.
Immunolocalization of Rh and RhAG in K562 cells To further illustrate the results obtained by flow cytometry and immunoprecipitation analysis, we performed fluorescence microscopy analysis of transfected K562 cells after labeling with the LOR-15C9 anti-RhD and the LA18.18 anti-RhAG antibodies. As shown in Figure 9, the membrane of K562/RhD cells was clearly stained by anti-RhAG, and a faint staining by anti-RhD could be detected despite the relatively low surface expression of RhD in these cells (7800 molecules/cell; Table 2). As a control, no membrane staining was detectable when the anti-RhD MAb was replaced by an anti-K1 human antibody (not shown), the K1 antigen not being expressed in K562 cells. The plasma membrane of K562/RhD cells was not stained anymore by anti-RhAG and anti-RhD MAbs after TPA treatment. The diffuse intracellular staining observed in TPA-treated cells should not be attributed to an intracellular accumulation of the RhAG and RhD polypeptides because of the high cytoplasmic background also observed in these cells with the anti-K1 negative control (not shown). The cell membrane of untreated or TPA-treated K562/RhAG cells was stained only by anti-RhAG MAb. Finally, the plasma membrane of K562/RhD/RhAG cells was stained by both the anti-RhAG (green fluorescence) and anti-RhD (red fluorescence) antibodies, and in contrast to K562/RhD cells, the same image was obtained after TPA treatment of these cells. Because the LOR-15C9 anti-RhD antibody has been previously shown to recognize the denatured RhD polypeptide in SDS gels32 and the purified RhD polypeptide (without RhAG),49 these results indicate that even when a large amount of RhD transcript is produced, as in TPA-treated K562/RhD cells, the lack of Rh antigens in the absence of RhAG is the result of nonexpression of the Rh polypeptide per se at the cell surface and not of a conformational change preventing accessibility of antibody epitopes.
In this paper, we report the expression of recombinant RhD and RhAG polypeptides following a standard plasmid transfection of HEK293 and K562 cells. This approach was used to demonstrate that surface expression of Rh depends on coexpression of RhAG, as previously suggested by molecular genetic analysis of Rhnull variants. First, HEK293 and HEK293/RhAG cells were transiently transfected with the RhD cDNA. As previously shown in the green monkey kidney COS-1 cells,50 our present study confirmed that cell-surface expression of recombinant RhAG glycoprotein could be achieved in nonerythroid cells. Furthermore, whereas surface expression of RhD was not recognized in stable COS-1 cells carrying both RhD and RhAG cDNAs,50 we were able to detect cell-surface expression of RhD in HEK293/RhAG cells but not in HEK293 cells, both transfected with the RhD cDNA. The very high expression level of recombinant RhAG in HEK293 cells as compared with COS-1 cells (not shown) might account for this apparent discrepancy. This result showed for the first time that transfected RhAG is able to influence the cell-surface expression of RhD in nonerythroid cells. However, because of the very different expression levels of recombinant RhAG and RhD in HEK293/RhAG/RhD cells, we assumed that this nonerythroid expression system is currently not suitable for investigation of the assembly of the Rh-RhAG complex, in which 2 RhAG polypeptides associate with 2 Rh polypeptides in the native RBC membrane.3 Erythroid K562 cells exhibiting endogenous expression of RhAG have recently proved to be particularly useful for demonstrating the genetic basis of the major Rh antigens using a retroviral expression system.27-30 In the present study, using a standard plasmid cell transfection, we were able to detect a significant surface expression of recombinant RhD despite a relatively low expression of endogenous RhAG in these K562 cells (MFI 35-40) as compared with the high expression level of recombinant RhAG in HEK293/RhAG cells (MFI 362). Therefore, to investigate the role of erythroid-specific proteins involved in the Rh complex assembly, such an erythroid system was found to be more suitable than the HEK293 model described above. Because of the reduced growth rates of G418-resistant/Rh-expressing cells compared with that of G418-resistant/non-Rh-expressing cells (doubling time, 27 hours versus 18 hours; not shown), a magnetic bead-based enrichment step was necessary for the isolation of a stable K562/RhD clone. Because of the rather low expression level of RhD antigen in K562/RhD cells (<10 000 copies/cell), these cells were treated by TPA, a phorbol ester described as an inducer of the CMV-based promoters,46 like those present in the vectors used in this study. However, whereas the amount of RhD transcripts was found to be substantially increased by TPA cell treatment, the amount of RhD antigen detected at the surface of K562/RhD cells was dramatically reduced. Because TPA has also been described as a negative effector of erythroid-specific promoters,43,44 we assumed that this unexpected result could account for a modulation of Rh membrane expression by an erythroid-specific protein whose expression was down-regulated by TPA. Among such proteins, the RhAG glycoprotein, whose expression is under the control of an erythroid-specific promoter,51,52 was the best candidate. To analyze the effect of RhAG expression levels on RhD surface expression, we transiently or stably transfected K562 and K562/RhD cells with RhAG cDNA. We found that cell-surface expression of RhAG in K562/RhAG cells could be dramatically increased by enhancing the recombinant RhAG transcript level by TPA treatment. This result indicated that, at least in K562 cells, RhAG antigen level is not limited by the absence of Rh, as previously postulated,48 but is rather regulated at the transcriptional level. However, mutations of the RH genes identified in Rhnull individuals of the amorph type are associated with a severely reduced amount of RhAG polypeptide on RBCs.1 These apparently contradictory results obtained with nucleated cells and mature RBCs suggest that Rh might be involved in the stability of RhAG once expressed at the cell membrane, rather than in the dynamic translocation process of RhAG toward the membrane. According to this hypothesis, the membrane instability of RhAG in the absence of Rh is not observed in nucleated cells, presumably because of the constant neosynthesis of RhAG polypeptide. Although the underglycosylation of RhAG in Rhnull cells suggested that the transit time of RhAG in the Golgi might be regulated by Rh,53 our present immunoprecipitation studies failed to reveal any modification of RhAG glycosylation between wild-type and RhD-transfected K562 cells (Figure 8). This discrepancy may be explained by a defect of K562 cells in some glycosylation branching enzymes, as previously illustrated by the incomplete glycosylation of glycophorins A and C in K562 cells as compared with late erythroid precursors.54 Flow cytometric analysis of TPA-treated and TPA-untreated K562/RhD
cells transiently transfected by RhAG revealed that only the
subpopulation of cells that overexpressed recombinant RhAG also
overexpressed the RhD antigen. Moreover, as recently described for band
3 and GPA using a similar expression system,55 a linear correlation between RhAG and RhD antigen expression levels was observed. The regulation of RhD and RhAG antigen coexpression was
further investigated in K562 cells stably expressing both recombinant
RhD and RhAG proteins (clone K562/RhD/RhAG) by analyzing the effect of
different times of TPA treatment. At first, the 2-fold overexpression
of RhAG obtained after stable transfection of RhAG cDNA in K562/RhD
cells was found to be associated with a 3-fold enhancement of RhD
expression. Most important, TPA treatment of these cells (K562/RhD/RhAG
transfectants), in contrast to that of K562/RhD cells, did not lead to
a down-regulation of RhD expression. We assumed that this different
regulation of RhD by TPA treatment resulted from the up-regulation of
recombinant RhAG in K562/RhD/RhAG cells as opposed to the
down-regulation of endogenous RhAG in K562/RhD cells (Figure
10).
TPA treatment of K562/RhD/RhAG cells, although not resulting in a down-regulation of RhD expression as in K562 or K562/RhAG cells, did not result in an up-regulation of RhD as observed for RhAG (Table 2; Figure 10). Furthermore, after 48 hours of TPA treatment, the RhAG surface expression in K562/RhD/RhAG cells was similar to that found in adult RBCs (180 000-200 000 copies/cell),1 whereas the level of recombinant RhD membrane expression was still largely lower (23 800 copies/cell) than that found in RBCs (100 000-200 000 copies/cell). This observation suggests that, beside the clear role of RhAG as a strictly required factor, the potential role of other protein(s), missing or weakly expressed in K562 cells, for optimal membrane expression of the RhD antigen should be investigated. It has been reported that the cell-surface reactivity of Rh antigens in K562 cells could be enhanced by expression of recombinant band 3,56 but it was subsequently shown that band 3 exhibits a lower affinity for RhD-RhAG than for RhCcEe-RhAG complexes.57 Furthermore, the data presented in these 2 papers showed that recombinant band-3 expression resulted in a more drastic increase in RhAG expression as compared with Rh. Together with our present results, these studies also suggest that RhD expression in K562 cells could not be enhanced beyond a certain level by increasing RhAG expression, either by TPA treatment or by band-3 coexpression. Therefore, it is unlikely that band 3 is the only missing factor in K562 cells required to reach an RhD expression level similar to that observed in mature RBCs and to that of RhAG. Given the recent studies showing that Rh and RhAG proteins are linked to the membrane skeleton,47,58 the putative role of erythroid-specific cytoskeletal protein(s) that would stabilize RhD cell-surface expression and that might be down-regulated by TPA treatment should also be evoked. Characterization of the cytoskeletal and cytoplasmic partners of the Rh and Rh-related polypeptides and of their role in the membrane expression of Rh antigens should certainly represent one of the next important steps in the analysis of Rh complex biosynthesis.
We thank Drs C. Lopez and C. Rahuel from our institute for the gift of CD55 and GPA probes, E. Collec from our institute for the pcDNA3/K2 expression vector, and Dr P. Rameau (INSERM U362, Villejuif, France) for cell-sorting experiments.
Submitted October 15, 2001; accepted March 20, 2002.
Supported in part by the Institut National de la Santé et de la Recherche Médicale.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Yves Colin, INSERM U76, INTS, 6 Rue Alexandre Cabanel, 75015 Paris, France; e-mail: colin{at}idf.inserm.fr.
1. Cartron JP. RH blood group system and molecular basis of Rh-deficiency. Baillieres Best Pract Res Clin Haematol. 1999;12:655-689[Medline] [Order article via Infotrieve]. 2. Huang CH, Liu PZ, Cheng JG. Molecular biology and genetics of the Rh blood group system. Semin Hematol. 2000;37:150-165[CrossRef][Medline] [Order article via Infotrieve].
3.
Eyers SA, Ridgwell K, Mawby WJ, Tanner MJ.
Topology and organization of human Rh (rhesus) blood group-related polypeptides.
J Biol Chem.
1994;269:6417-6423
4.
Agre P, Cartron JP.
Molecular biology of the Rh antigens.
Blood.
1991;78:551-563 5. Cartron JP, Agre P. Rh blood group antigens: protein and gene structure. Semin Hematol. 1993;30:193-208[Medline] [Order article via Infotrieve]. 6. Anstee DJ, Tanner MJ. Biochemical aspects of the blood group Rh (rhesus) antigens. Baillieres Clin Haematol. 1993;6:401-422[Medline] [Order article via Infotrieve]. 7. Cartron JP. Defining the Rh blood group antigens. Biochemistry and molecular genetics. Blood Rev. 1994;8:199-212[CrossRef][Medline] [Order article via Infotrieve]. 8. Kitano T, Sumiyama K, Shiroishi T, Saitou N. Conserved evolution of the Rh50 gene compared to its homologous Rh blood group gene. Biochem Biophys Res Commun. 1998;249:78-85[CrossRef][Medline] [Order article via Infotrieve]. 9. Matassi G, Cherif-Zahar B, Pesole G, Raynal V, Cartron JP. The members of the RH gene family (RH50 and RH30) followed different evolutionary pathways. J Mol Evol. 1999;48:151-159[CrossRef][Medline] [Order article via Infotrieve]. 10. Huang CH, Liu PZ. New insights into the Rh superfamily of genes and proteins in erythroid cells and nonerythroid tissues. Blood Cells Mol Dis. 2001;27:90-101[CrossRef][Medline] [Order article via Infotrieve]. 11. Cartron JP, Colin Y. Structural and functional diversity of blood group antigens. Transfus Clin Biol. 2001;8:163-199[CrossRef][Medline] [Order article via Infotrieve].
12.
Wagner FF, Flegel WA.
RHD gene deletion occurred in the Rhesus box.
Blood.
2000;95:3662-3668
13.
Colin Y, Cherif-Zahar B, Le Van Kim C, Raynal V, Van Huffel V, Cartron JP.
Genetic basis of the RhD-positive and RhD-negative blood group polymorphism as determined by Southern analysis.
Blood.
1991;78:2747-2752
14.
Hartel-Schenk S, Agre P.
Mammalian red cell membrane Rh polypeptides are selectively palmitoylated subunits of a macromolecular complex.
J Biol Chem.
1992;267:5569-5574 15. Matassi G, Cherif-Zahar B, Raynal V, Rouger P, Cartron JP. Organization of the human RH50A gene (RHAG) and evolution of base composition of the RH gene family. Genomics. 1998;47:286-293[CrossRef][Medline] [Order article via Infotrieve].
16.
Huang CH.
The human Rh50 glycoprotein gene. Structural organization and associated splicing defect resulting in Rh(null) disease.
J Biol Chem.
1998;273:2207-2213 17. Ridgwell K, Spurr NK, Laguda B, MacGeoch C, Avent ND, Tanner MJ. Isolation of cDNA clones for a 50 kDa glycoprotein of the human erythrocyte membrane associated with Rh (rhesus) blood-group antigen expression. Biochem J. 1992;287:223-228[Medline] [Order article via Infotrieve]. 18. Cartron JP. Molecular basis of red cell protein antigen deficiencies. Vox Sang. 2000;78:7-23[CrossRef][Medline] [Order article via Infotrieve].
19.
Lindberg FP, Bullard DC, Caver TE, Gresham HD, Beaudet AL, Brown EJ.
Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient mice.
Science.
1996;274:795-798 20. Mouro-Chanteloup I, Brown EJ, Johansen M, Cartron JP, Colin Y. Normal red cell membrane expression of Rh and Rhag polypeptides on CO47-deficient mice. Vox Sang. 2000;78(suppl 1):P030(abstract). 21. Cherif-Zahar B, Raynal V, Gane P, et al. Candidate gene acting as a suppressor of the RH locus in most cases of Rh-deficiency. Nat Genet. 1996;12:168-173[CrossRef][Medline] [Order article via Infotrieve]. 22. Anstee DJ, Holmes CH, Judson PA, Tanner MJA. Protein blood group antigens of the human red cell. In: Agre P,Cartron JP, eds. The Use of Monoclonal Antibodies to Determine the Distribution of Red Cell Surface Proteins on Cells and Tissues. Baltimore, MD: The Johns Hopkins University Press; 1992:170-181.
23.
Suyama K, Lunn R, Haller S, Goldstein J.
Rh(D) antigen expression and isolation of a new Rh(D) cDNA isoform in human erythroleukemic K562 cells.
Blood.
1994;84:1975-1981
24.
Cherif-Zahar B, Matassi G, Raynal V, et al.
Molecular defects of the RHCE gene in Rh-deficient individuals of the amorph type.
Blood.
1998;92:639-646 25. Bony V, Gane P, Bailly P, Cartron JP. Time-course expression of polypeptides carrying blood group antigens during human erythroid differentiation. Br J Haematol. 1999;107:263-274[CrossRef][Medline] [Order article via Infotrieve].
26.
Southcott MJ, Tanner MJ, Anstee DJ.
The expression of human blood group antigens during erythropoiesis in a cell culture system.
Blood.
1999;93:4425-4435
27.
Smythe JS, Avent ND, Judson PA, Parsons SF, Martin PG, Anstee DJ.
Expression of RHD and RHCE gene products using retroviral transduction of K562 cells establishes the molecular basis of Rh blood group antigens.
Blood.
1996;87:2968-2973 28. Smythe JS, Anstee DJ. Expression of C antigen in transduced K562 cells. Transfusion. 2001;41:24-30[CrossRef][Medline] [Order article via Infotrieve]. 29. Liu W, Smythe JS, Scott ML, Jones JW, Voak D, Avent ND. Site-directed mutagenesis of the human D antigen: definition of D epitopes on the sixth external domain of the D protein expressed on K562 cells. Transfusion. 1999;39:17-25[CrossRef][Medline] [Order article via Infotrieve].
30.
Liu W, Avent ND, Jones JW, Scott ML, Voak D.
Molecular configuration of Rh D epitopes as defined by site-directed mutagenesis and expression of mutant Rh constructs in K562 erythroleukemia cells.
Blood.
1999;94:3986-3996 31. Lomas C, McColl K, Tippett P. Further complexities of the Rh antigen D disclosed by testing category DII cells with monoclonal anti-D. Transfus Med. 1993;3:67-69[Medline] [Order article via Infotrieve]. 32. Apoil PA, Reid ME, Halverson G, et al. A human monoclonal anti-D antibody which detects a nonconformation-dependent epitope on the RhD protein by immunoblot. Br J Haematol. 1997;98:365-374[CrossRef][Medline] [Order article via Infotrieve]. 33. Goossens D, Champomier F, Rouger P, Salmon C. Human monoclonal antibodies against blood group antigens. Preparation of a series of stable EBV immortalized B clones producing high levels of antibody of different isotypes and specificities. J Immunol Methods. 1987;101:193-200[CrossRef][Medline] [Order article via Infotrieve].
34.
Hermand P, Mouro I, Huet M, et al.
Immunochemical characterization of rhesus proteins with antibodies raised against synthetic peptides.
Blood.
1993;82:669-676
35.
Le van Kim C, Mouro I, Cherif-Zahar B, et al.
Molecular cloning and primary structure of the human blood group RhD polypeptide.
Proc Natl Acad Sci U S A.
1992;89:10925-10929
36.
Fouchet C, Gane P, Huet M, et al.
A study of the coregulation and tissue specificity of XG and MIC2 gene expression in eukaryotic cells.
Blood.
2000;95:1819-1826
37.
Rahuel C, Le Van Kim C, Mattei MG, Cartron JP, Colin Y.
A unique gene encodes spliceoforms of the B-cell adhesion molecule cell surface glycoprotein of epithelial cancer and of the Lutheran blood group glycoprotein.
Blood.
1996;88:1865-1872 38. Rasamoelisolo M, Rahuel C, Loirat MJ, Willem C, Cartron JP, Blanchard D. Immunochemical characterisation of monoclonal antibodies directed to glycophorins A and/or B. Transfus Clin Biol. 1997;4:91-96[CrossRef][Medline] [Order article via Infotrieve]. 39. Stamenkovic I, Amiot M, Pesando JM, Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell. 1989;56:1057-1062[CrossRef][Medline] [Order article via Infotrieve]. 40. Caras IW, Davitz MA, Rhee L, Weddell G, Martin DW Jr, Nussenzweig V. Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature. 1987;325:545-549[CrossRef][Medline] [Order article via Infotrieve].
41.
Campbell IG, Freemont PS, Foulkes W, Trowsdale J.
An ovarian tumor marker with homology to vaccinia virus contains an IgV-like region and multiple transmembrane domains.
Cancer Res.
1992;52:5416-5420
42.
El Nemer W, Rahuel C, Colin Y, Gane P, Cartron JP, Le Van Kim C.
Organization of the human LU gene and molecular basis of the Lu(a)/Lu(b) blood group polymorphism.
Blood.
1997;89:4608-4616
43.
Siebert PD, Fukuda M.
Regulation of glycophorin gene expression by a tumor-promoting phorbol ester in human leukemic K562 cells.
J Biol Chem.
1985;260:640-645
44.
Mignotte V, Navarro S, Eleouet JF, Zon LI, Romeo PH.
The extinction of erythroid genes after tetradecanoylphorbol acetate treatment of erythroleukemic cells correlates with down-regulation of the tissue-specific factors NF-E1 and NF-E2.
J Biol Chem.
1990;265:22090-22092
45.
Belhacene N, Maulon L, Guerin S, et al.
Differential expression of the Kell blood group and CD10 antigens: two related membrane metallopeptidases during differentiation of K562 cells by phorbol ester and hemin.
FASEB J.
1998;12:531-539 46. Chan YJ, Chiou CJ, Huang Q, Hayward GS. Synergistic interactions between overlapping binding sites for the serum response factor and ELK-1 proteins mediate both basal enhancement and phorbol ester responsiveness of primate cytomegalovirus major immediate-early promoters in monocyte and T-lymphocyte cell types. J Virol. 1996;70:8590-8605[Abstract]. 47. Gane P, Le Van Kim C, Bony V, et al. Flow cytometry analysis of the association between blood group-related proteins and the detergent-insoluble material of K562 cells and erythroid precursors. Br J Haematol. 2001;113:1-10[CrossRef][Medline] [Order article via Infotrieve]. 48. Suyama K, Lunn R, Smith BL, Haller S. Expression of the Rh-related glycoprotein (Rh50). Acta Haematol. 1998;100:181-186[CrossRef][Medline] [Order article via Infotrieve]. 49. Cochet S, Blancher A, Roubinet F, Hattab C, Cartron JP, Bertrand O. Immunopurification of the blood group RhD protein from human erythrocyte membranes. J Chromatogr B Biomed Sci Appl. 1999;735:207-217[CrossRef][Medline] [Order article via Infotrieve].
50.
Suyama K, Li H, Zhu A.
Surface expression of Rh-associated glycoprotein (RhAG) in nonerythroid COS-1 cells.
Blood.
2000;95:336-341 51. Iwamoto S, Omi T, Yamasaki M, Okuda H, Kawano M, Kajii E. Identification of 5' flanking sequence of RH50 gene and the core region for erythroid-specific expression. Biochem Biophys Res Commun. 1998;243:233-240[CrossRef][Medline] [Order article via Infotrieve].
52.
Iwamoto S, Suganuma H, Kamesaki T, Omi T, Okuda H, Kajii E.
Cloning and characterization of erythroid-specific DNase I-hypersensitive site in human rhesus-associated glycoprotein gene.
J Biol Chem.
2000;275:27324-27331
53.
Ridgwell K, Eyers SA, Mawby WJ, Anstee DJ, Tanner MJ.
Studies on the glycoprotein associated with Rh (rhesus) blood group antigen expression in the human red blood cell membrane.
J Biol Chem.
1994;269:6410-6416
54.
Villeval JL, Le Van Kim C, Bettaieb A, et al.
Early expression of glycophorin C during normal and leukemic human erythroid differentiation.
Cancer Res.
1989;49:2626-2632 55. Young MT, Beckmann R, Toye AM, Tanner MJ. Red-cell glycophorin A-band 3 interactions associated with the movement of band 3 to the cell surface. Biochem J. 2000;350:53-60[Medline] [Order article via Infotrieve].
56.
Beckmann R, Smythe JS, Anstee DJ, Tanner MJ.
Functional cell surface expression of band 3, the human red blood cell anion exchange protein (AE1), in K562 erythroleukemia cells: band 3 enhances the cell surface reactivity of Rh antigens.
Blood.
1998;92:4428-4438
57.
Beckmann R, Smythe JS, Anstee DJ, Tanner MJ.
Coexpression of band 3 mutants and Rh polypeptides: differential effects of band 3 on the expression of the Rh complex containing D polypeptide and the Rh complex containing CcEe polypeptide.
Blood.
2001;97:2496-2505 58. Gimm A, Mouro I, Lambin P, Mohandas N, Cartron JP. Vox Sang. 2000;78(suppl 1):14(abstract).
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  G. F. Kormoczi, E.-M. Dauber, O. A. Haas, T. J. Legler, F. B. Clausen, G. Fritsch, M. Raderer, C. Buchta, A. L. Petzer, D. Schonitzer, et al. Mosaicism due to myeloid lineage restricted loss of heterozygosity as cause of spontaneous Rh phenotype splitting Blood, September 15, 2007; 110(6): 2148 - 2157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ripoche, O. Bertrand, P. Gane, C. Birkenmeier, Y. Colin, and J.-P. Cartron Human Rhesus-associated glycoprotein mediates facilitated transport of NH3 into red blood cells PNAS, December 7, 2004; 101(49): 17222 - 17227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Nicolas, C. Le Van Kim, P. Gane, C. Birkenmeier, J.-P. Cartron, Y. Colin, and I. Mouro-Chanteloup Rh-RhAG/Ankyrin-R, a New Interaction Site between the Membrane Bilayer and the Red Cell Skeleton, Is Impaired by Rhnull-associated Mutation J. Biol. Chem., July 3, 2003; 278(28): 25526 - 25533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Quentin, D. Eladari, L. Cheval, C. Lopez, D. Goossens, Y. Colin, J.-P. Cartron, M. Paillard, and R. Chambrey RhBG and RhCG, the Putative Ammonia Transporters, Are Expressed in the Same Cells in the Distal Nephron J. Am. Soc. Nephrol., March 1, 2003; 14(3): 545 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. F. Wagner, J. Poole, and W. A. Flegel Scianna antigens including Rd are expressed by ERMAP Blood, January 15, 2003; 101(2): 752 - 757. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
/
) cells were incubated for 3 hours
with [35S]-methionine. Cell lysates from K562
(W.T.) and K562/RhD/RhAG cells were used for immunoprecipitation with
the MPC8 anti-Rh polyclonal antibody (PAb) (A) or the LA18.18
anti-RhAG mMAb (B) and Protein A-Sepharose. The isolated proteins were
separated by 10% SDS-PAGE under reducing conditions. Low molecular
weight proteins from Biorad were used as standards. Arrows
indicate the 32-kd Rh and RhAG proteins.
